Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giuseppe Santabarbara
Observed names:
G Santabarbara,
G. Santabarbara
Institution:
Azienda Ospedaliera S.Giuseppe Moscati
Observed institutions:
University of Campania "Luigi Vanvitelli",
Azienda Ospedaliera S.Giuseppe Moscati,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
ORCID:
0000-0002-8317-0907
Observed ORCID:
0000-0002-8317-0907
OpenAlex ID:
A5018958639
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial
2021
·
Erika Martinelli
, Giulia Martini
, et al.
·
JAMA Oncology
·
194
Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy
2015
·
Giuseppe Santabarbara
, Paolo Maione
, et al.
·
Expert Opinion on Pharmacotherapy
·
62
Neo-adjuvant and adjuvant chemotherapy of gastric cancer
2007
·
F. De Vita
, F. Giuliani
, et al.
·
Annals of Oncology
·
62
Valorization of Olive Mill Wastewater by Membrane Processes to Recover Natural Antioxidant Compounds for Cosmeceutical and Nutraceutical Applications or Functional Foods
2018
·
Alberto Alfano
, Luisana Corsuto
, et al.
·
Antioxidants
·
58
PDF
Current status of targeted therapies in advanced gastric cancer
2012
·
Ferdinando De Vita
, Francesco Giuliani
, et al.
·
Expert Opinion on Therapeutic Targets
·
42
Selumetinib for the treatment of non-small cell lung cancer
2017
·
Francesca Casaluce
, Assunta Sgambato
, et al.
·
Expert Opinion on Investigational Drugs
·
34
Novel immunotherapy in the treatment of advanced non-small cell lung cancer
2016
·
G. Santabarbara
, P. Maione
, et al.
·
Expert Review of Clinical Pharmacology
·
29
Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer
2008
·
F. Iovino
, F. Ferraraccio
, et al.
·
Cancer Investigation
·
27
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
2015
·
Emanuela Rossi
, Assunta Sgambato
, et al.
·
Expert Review of Clinical Pharmacology
·
26
397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
2020
·
E. Martinelli
, G. Martini
, et al.
·
Annals of Oncology
·
23
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020
·
Margaret Ottaviano
, Marcello Curvietto
, et al.
·
Journal for ImmunoTherapy of Cancer
·
19
PDF
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
2024
·
Antonio Avallone
, Francesco Giuliani
, et al.
·
Journal of Clinical Oncology
·
16
PDF
Overcoming Resistance to EGFR Inhibitors in NSCLC
2016
·
Paolo Maione
, Paola C. Sacco
, et al.
·
Reviews on Recent Clinical Trials
·
16
Optimal drugs for second-line treatment of patients with small-cell lung cancer
2016
·
Antonio Rossi
, Paola Claudia Sacco
, et al.
·
Expert Opinion on Pharmacotherapy
·
15
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
2025
·
D. Ciardiello
, G. Martini
, et al.
·
Annals of Oncology
·
14
PDF
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial
2025
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Open
·
13
PDF
Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
2022
·
Antonio Avallone
, Francesco Giuliani
, et al.
·
Journal of Clinical Oncology
·
13
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
2021
·
Davide Ciardiello
, Vincenzo Famiglietti
, et al.
·
Cancers
·
11
PDF
The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer
2017
·
Paolo Maione
, Assunta Sgambato
, et al.
·
Current Medicinal Chemistry
·
11
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer
2016
·
Giuseppe Santabarbara
, Paolo Maione
, et al.
·
Annals of Translational Medicine
·
11
PDF
Developments in pharmacotherapy for treating metastatic non-small cell lung cancer
2017
·
Antonio Rossi
, Paola Claudia Sacco
, et al.
·
Expert Opinion on Pharmacotherapy
·
10
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.
2021
·
Giulia Martini
, Stefania Napolitano
, et al.
·
Journal of Clinical Oncology
·
9
Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
2019
·
E. Martinelli
, T. Troiani
, et al.
·
Annals of Oncology
·
6
PDF
New approach to implement cancer patient care: The valutazione percorso rete oncologica campana (ValPeROC)‐experience from an Italian oncology network
2022
·
Anna Crispo
, Giorgia Rivieccio
, et al.
·
European Journal of Cancer Care
·
4
PDF
The safety of second-line treatment options for non-small cell lung cancer
2017
·
Antonio Rossi
, Paolo Maione
, et al.
·
Expert Opinion on Drug Safety
·
4
Show more works
View as search
Works count:
40
Citation count:
742
H-index:
14
I10-index:
21
Year
Topic
Type